Vés al contingut
publicaciones

Articles científics publicats pels investigadors del Barcelonaβeta Brain Research Center (BBRC), relacionats amb la malaltia d'Alzheimer, la neuroimatge, la memòria i les malalties neurodegeneratives, entre altres camps.

  • Serrano-Pozo A, Escott-Price V, Grinberg LT, Pascoal T, Suárez-Calvet M, Dubois B, Sperling RA.

    Alzheimer's disease

    Lancet
    Abstract

    Alzheimer's disease is the leading cause of dementia and among the top ten leading causes of death in high-income countries. Exponential advances in epidemiology, genetics, diagnostic imaging and...

  • Suárez-Calvet M, Salvadó G, de Fortuny BB, Del Campo M. 

    Blood biomarkers for Alzheimer's disease: from detection to decisions

    Lancet
  • Fernández-Lebrero A, Jiménez-Balado J, García-Escobar G, Contador J, Estraguès-Gázquez I, Peraferrer-Montesinos L, Suárez-Pérez A, Manero-Borràs RM, Beltrán B, Gramegna L, Campello AR, Palacio-Gili A, Grau O, Suárez-Calvet M, Ois A, Puig-Pijoan A, Navalpotro-Gómez I.

    CSF Biomarker Profile of Cerebral Amyloid Angiopathy: Diagnostic Performance and Imaging Correlates in a Hospital-Based Neurology Cohort

    European Journal of Neurology
    Abstract

    Background: Cerebral amyloid angiopathy (CAA) frequently co-occurs with Alzheimer's disease (AD), complicating diagnosis in patients with cognitive impairment. The CSF biomarker profile of CAA remains...

  • Toccaceli Blasi M, Salzillo M, Buscarnera S, Nuti F, Stanziale C, Pecorari C, Ottone DA, Salati E, D'Antonio F, Canevelli M, Bruno G.

    A diary-based approach to improve neuropsychiatric symptom assessment in dementia: A cross-sectional comparison with the neuropsychiatric inventory

    Journal of Alzheimer's Disease
    Abstract

    BackgroundNeuropsychiatric symptoms (NPS) are among the most challenging manifestations of dementia. Currently available assessment tools often fail to fully capture their complexity. Thus, novel...

  • Shekari M, Escalante AG, Milà-Alomà M, Falcon C, López-Martos D, Sánchez-Benavides G, Brugulat-Serrat A, Niñerola-Baizán A, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Montoliu-Gaya L, Snellman A, Day TA, Dage JL, Ortiz-Romero P, Tonietto M, Borroni E, Klein G, Kollmorgen G, Carboni M, Quijano-Rubio C, Vanmechelen E, Minguillón C, Fauria K, Perissinotti A, Molinuevo JL, Zetterberg H, Blennow K, Grau-Rivera O, Suárez-Calvet M, Gispert JD; ALFA Study.

    Associations of 18F-RO-948 tau PET with fluid AD biomarkers, Centiloid, and cognition in early AD continuum

    Alzheimer's & Dementia
    Abstract

    Introduction: We examined neurofibrillary tangle (NFT) pathology using 18F-RO-948 tau positron emission tomography (PET) in cognitively unimpaired individuals and its associations with amyloid plaques...

  • Hortsch S, Domenico AD, Borlinghaus N, Caley D, Kaminioti-Dumont L, Jeppesen SB, González-Escalante A, Ritchie C, Frederiksen KS, Suárez-Calvet M.

    Performance of a fully automated plasma tau phosphorylated at threonine 217 immunoassay to reflect amyloid-beta burden in an unselected cohort representative of clinical practice

    The journal of prevention of Alzheimer's Disease
    Abstract

    Background: With the emergence of disease-modifying anti-amyloid-beta (Aβ) therapies for Alzheimer's disease (AD), early and accurate quantitative measures of Aβ burden are critical. Blood-based...

  • Reiman EM, Alexander RC, Langbaum JB, Aisen PS, Ashton N, Atri A, Barbarino P, Byrd GS, Feldman HH, Fowler NR, Ghisays V, Grill JD, Hassenstab J, Heaton GR, Herring WL, Jack CR Jr, Johnson SC, Karlawish J, Keach NL, Kivipelto M, Krumholz HM, Largent EA, MaGee-Rodgers T, McDade E, Mielke MM, Molina-Henry D, Petersen RC, Rabinovici GD, Ritchie C, Schindler SE, Sperling RA, Suárez-Calvet M, Vradenburg G, Weiner MW, Welsh-Bohmer KA, Zetterberg H, Zuendel MT, Mattke S, Cummings JL

    A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA

    The Lancet Neurology
    Abstract

    Antibody therapies can remove amyloid plaques from the brain and slow cognitive decline in people with Alzheimer's disease who are mildly impaired. These drugs are now being evaluated in participants...

  • Timsina J, Jiang C, McCartney DL, Tao F, Dalmasso MC, Najar J, Anastasi F, Ohlei O, Puerta Fuentes R, Yang C, Bradley J, Western D, Ali M, Wang C, Yang C, Wu Y, Liu M, Budde J, Williams J, Mahoney R, Castillo Morales A, Hohman TJ, Dumitrescu L, Wang TC, Tesi N, Kern S, Waern M, Skoog I, van Harten A, Pijnenburg YAL, van der Flier WM, Sánchez-Juan P, Rodriguez-Rodriguez E, Kleineidam L, Peters O, Schneider A, Küçükali F, Bellenguez C, Grenier-Boley B, Heikkinen S, de Rojas I, Rujescu D, Scherbaum N, Hausner L, Düzel E, Grimmer T, Wiltfang J, Vandenberghe R, Engelborghs S, Heilmann-Heimbach S, Schmid M, Tegos T, Scarmeas N, Dols-Icardo O, Moreno F, Pérez-Tur J, Bullido MJ, Sánchez-Valle R, Álvarez V, García-González P, Mir P, Real LM, Piñol-Ripoll G, García-Alberca JM, Seelaar H, Ramakers I, Papma J, Hulsman M, Laske C, Teipel S, Priller J, Perneczky R, Buerger K, Nöthen MM, Lewczuk P, Kornhuber J, Hampel H, Giegling I, Goldhardt O, Diehl-Schmid J, Andrade V, Heneka MM, Frölich L, Vogelgsang J, Graff C, Thonberg H, Ullgren A, Papenberg G, Deleuze JF, Dufouil C, Wagner M, Jessen F, Holstege H, van Duijn C, Lebouvier T, Hannon O, Leinonen V, Soininen H, Herukka SK, Giedraitis V, Löwenmark M, Kilander L, Genius P, Rodríguez B, Luckett ES, Navarro A, Cano A, Marquié M, Blennow K, Zetterberg H, Lleo A, Boada M, Ruiz A, Lee VM, Van Deerlin VM, Deming Y, Johnson SC, Engelman CD, Pastor P, Alvarez I, Peskind ER, Heslegrave AJ, Saykin AJ, Nho K, Schindler SE, Morris JC, Holtzman DM, McDade E, Renton AE, Goate A, Ibanez L, Riemenschneider M, Albert MS, Laws SM, Porter T, O'Brien EK, Shaw LM, Tijms BM, Ingelsson M, Visser PJ, Hiltunen M, Sleegers K, Ritchie CW, Sims R, Belloy M, Lambert JC, Vilor-Tejedor N, Fernández MV, Li QS, Nagle MW, Marioni RE, Ramirez A, Bertram L, van der Lee SJ, Cruchaga C. 

    GWAS meta-analysis of cerebrospinal fluid Alzheimer's biomarkers reveals loci regulating lipids, brain volume and autophagy

    Nature Communications
    Abstract

    Cerebrospinal fluid amyloid beta 42, total tau, and phosphorylated tau 181 are well accepted markers of Alzheimer's disease. These biomarkers better reflect disease pathogenesis compared to clinical...

  • Kassinopoulos M, Montesinos P, Falcon C, Huguet J, Minguillon C, Fauria K, Kollmorgen G, Quijano-Rubio C, Molinuevo JL, Grau-Rivera O, Zetterberg H, Blennow K, Suárez-Calvet M, Sanchez-Gonzalez J, Gispert JD; ALFA study

    Intracellular fluid accumulation underlies brain volume increases in early Alzheimer's disease

    Brain Communications
    Abstract

    In the preclinical stages of Alzheimer's disease, increased brain volume has been associated with amyloid-beta pathology, particularly in regions that undergo volume reductions as the disease...

  • Genius P, Fernández-Bonet A, Rodríguez-Fernández B, Gallay C, Gonzalez-Escalante A, Sánchez-Benavides G, López-Martos D, Esteller M, Navarro A, Gispert JD, Brugulat-Serrat A, Vilor-Tejedor N

    Sex-specific early cognitive changes are linked to global and pathway-specific genetic risk for Alzheimer's disease in at-risk individuals

    Biology of sex differences
    Abstract

    Alzheimer's disease (AD) is a progressive neurodegenerative condition in which genetic predisposition plays a key role, yet the sex-specific mechanisms linking genetic risk to early cognitive changes...